Medrad Stellant CT Injector System with Imaging System Interface Module
Medrad
FDA Clearance Information
The Medrad Stellant CT Injector System was cleared by the FDA through the 510(k) pathway on March 2, 2004. It is manufactured by Medrad and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- For the controlled injection of contrast media during CT imaging procedures.
- For use with compatible CT imaging systems through an imaging system interface.
- Intended for use by trained healthcare professionals in diagnostic imaging.
Clinical Applications
- Contrast-enhanced CT examinations of the head, neck, chest, abdomen, and pelvis.
- CT angiography when controlled intravenous contrast injection is required.
- Routine diagnostic CT studies requiring enhancement of internal organs, vessels, or other tissues.
- Use with compatible CT scanners to coordinate contrast injection with image acquisition.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system is designed for controlled delivery of contrast media through an intravenous access device; the access site and injection parameters must be selected for the examination and patient.
- Compatibility depends on the specific injector configuration, disposable syringe or tubing set, contrast medium, and CT scanner interface.
- This is a CT injector and is not an MRI-compatible injector unless the specific configuration is separately labeled for the MRI environment.
- Contrast administration requires screening for prior contrast reactions, kidney disease, pregnancy, and other patient-specific risks according to institutional protocols.
- The injector should be operated and maintained according to the manufacturer’s instructions, including inspection of disposables, air removal, pressure limits, alarms, and preventive maintenance.
Frequently Asked Questions
What are the clinical indications for Medrad Stellant CT Injector System?
The device is indicated for use in CT imaging procedures requiring contrast media injection, such as tumor ablation and coronary CT angiography.
What outcomes have been reported in clinical studies?
Studies have reported high efficiency and satisfactory performance in delivering consistent contrast media flow, enhancing imaging quality.
What complications have been reported?
Safety data indicate issues with visual air identification and cleaning ease, but no major adverse events were reported.